Case: In re Neurontin Antitrust Litigation, 2011 U.S. Dist. LEXIS 62032, MDL No. 1479, Master File No. 02-1390 (D.N.J. 6/9/2011).
Facts:
Direct purchasers of the drug Neurontin brought an antitrust lawsuit claiming that the drug’s two manufacturers took part in a scheme to delay market entry of a generic version of the drug. Part of the alleged scheme included defendants’ illegal promotion of Neurontin for off-label uses. Both defendants denied the off-label promotion in their Answers to the plaintiffs’ Complaint, but defendant Pfizer had previously pled guilty to the illegal marketing in a separate criminal case.
